Recruiting
Phase 1
Phase 2

Amiodarone Patch

Sponsor:

Helios Cardio Inc.

Code:

NCT06730828

Conditions

Atrial Fibrillation, Postoperative

Eligibility Criteria

Sex: All

Age: 20 - 70+

Healthy Volunteers: Not accepted

Interventions

The intervention includes Amiodarone-Infused CardiaMend patches (70mg, 150mg and 300mg)

Study Details

Brief summary:

The goal of this clinical trial is to is to test the safety of a new way to deliver a commonly used drug (amiodarone) used in heart surgery by placing a patch containing the drug directly on the heart instead of in an IV (vein). Participating subjects must be 20-85 year old males or females. Up to 80 participants having cardiac surgery at the University of Louisville will be involved in this study.

The main questions this study aims to answer are:

1. Is the patch safe?
2. Does the patch lower the rate of atrial fibrillation (irregular heart rhythm) after cardiac surgery?

Researchers will compare up to 3 different doses of the amiodarone patches (low, medium and high) to the usual treatment (Standard of Care) to see if there are differences (increases or decreases) in heart rhythms after cardiac surgery across study groups.

Participants will be placed in one of 4 study groups:

  • Standard of Care (20 participants)
  • Low dose patch (20 participants)
  • Medium dose patch (20 participants)
  • High dose patch (20 participants)

Participants will be monitored closely by their doctor(s) during the study and would:

  • Agree to participate after having their doctor, or a member of the team, explain the study in detail and allowing them to ask any questions they would like.
  • Sign an Informed Consent Form which will describe the study and tests in full.
  • Agree to have their doctor and his/her research team record your medical information, draw blood, and perform electrocardiograms, or EKGs (quick, painless test that measures the electrical activity of the heart) and echocardiograms (image of heart) to monitor their heart.
  • Agree to receive training on the portable EKG recorder and to use it at home approximately 30 days and 6 months after their surgery to monitor their heart.
  • Agree to return to the hospital approximately 30 days and 6 months after their surgery for a study visit.

Participant involvement will be approximately 7 months total.

Conditions

Atrial Fibrillation, Postoperative

Study ID

NCT06730828

Start date

Dec 16, 2024

Status verified date

Dec, 2024

Completion date

May, 2026

Anticipated

Primary completion date

Nov, 2025

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 20 - 70+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Subjects 20-85 years old.
  • Subjects able to give voluntary written informed consent, who understand and are willing to comply with study-related procedures.
  • Subjects scheduled to undergo open-chest cardiac surgery via complete median sternotomy.
  • Subjects in sinus rhythm at the time of office visit and during prior EKG (note: continuous EKG monitoring for 48 hours is not required).

Exclusion Criteria:

  • Subjects unable to give voluntary written informed consent, unlikely to cooperate, or legally incompetent, including subjects institutionalized by court or official order, or in a dependency relationship with testing center or investigator.
  • Subjects with a condition that could interfere with their ability to comply with the study.
  • Subjects participating in an interventional clinical study or who have participated in such study during the preceding 30 days.
  • Female subjects who are pregnant, breastfeeding, were pregnant within the last three months, or are planning to become pregnant during the study.
  • Subjects with active skin or deep infection at the site of implantation.
  • Subjects with a history of chronic wounds or wound-healing disorders.
  • Subjects with known connective tissue diseases (e.g. Ehlers-Danlos syndrome, Epidermolysis bullosa, Marfan syndrome, Osteogenesis imperfecta).
  • Subjects who are Immune-suppressed or with immune deficiency (properly managed diabetes mellitus is not an exclusion criterion).
  • Subjects on concomitant oral or IV systemic corticosteroid therapy and/or other constant anti-inflammatory therapies.
  • Subjects on the following medications with known interactions with amiodarone: doxorubicin, fosphenytoin, lopinavir-ritonavir, ledipasvir/sofosbuvir, quinidine , procainamide, disopyramide, other Vaughan William class III agents including dofetilide, dronedarone, ibutilide and vernakalant.
  • Subjects with coadministration of any medications which cause QT prolongation
  • Subjects with implantable cardiac devices (i.e., cardiac resynchronization therapy devices with and without defibrillator capabilities (CRTs and CRT-Ds), implantable cardioverter-defibrillators (ICD), and pacemakers).
  • Subjects with a known history of atrial fibrillation or paroxysmal atrial fibrillation.
  • Subjects with a history of ablation for atrial fibrillation.
  • Subjects already receiving amiodarone as a treatment for atrial fibrillation or ventricular arrhythmias.
  • Subjects with a disease of the left pleura, previous intervention in the left pleural space, or chest deformity.
  • Subjects with heart failure (BNP>1000), low ejection fraction (<35%), end-stage renal disease (on dialysis or GFR<20).
  • Subjects electing to receive an ablative procedure for atrial fibrillation during the index operation.
  • Subjects with prior cardiac surgery via sternotomy.

Study Design

Enrollment

80 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Prevention

Interventions and Outcome Measures

Arms

no intervention: Group 1: 20 subjects in the control group, which is the standard of care (i.e., no CardiaMend-Amioda

Subjects in treatment Group 1 (control) will receive no CardiaMend-Amiodarone patches.

experimental: Group 2: 20 subjects receiving CardiaMend-Amiodarone infused with 70 mg of amiodarone

Subjects in Group 2 (70 mg) will receive three patches each as follows:

  • One patch (5x6 cm) will be placed on top of the right atrium;
  • One patch (3x5 cm) will be placed within the transverse sinus near the dome of the left atrium; and
  • One patch (3x5 cm) will be placed within the oblique sinus on the posterior/inferior aspect of left atrium

experimental: Group 3: 20 subjects receiving CardiaMend-Amiodarone infused with 150 mg of amiodarone.

Subjects in Group 3 (150 mg) will receive three patches each as follows:

  • One patch (5x6 cm) will be placed on top of the right atrium;
  • One patch (3x5 cm) will be placed within the transverse sinus near the dome of the left atrium; and
  • One patch (3x5 cm) will be placed within the oblique sinus on the posterior/inferior aspect of left atrium

experimental: Group 4: 20 subjects receiving CardiaMend-Amiodarone infused with 300 mg of amiodarone.

Subjects in Group 4 (300 mg) will receive three patches each as follows:

  • One patch (5x6 cm) will be placed on top of the right atrium;
  • One patch (3x5 cm) will be placed within the transverse sinus near the dome of the left atrium; and
  • One patch (3x5 cm) will be placed within the oblique sinus on the posterior/inferior aspect of left atrium

Interventions

The intervention includes Amiodarone-Infused CardiaMend patches (70mg, 150mg and 300mg)

Intervention includes a topical, atrial-specific, amiodarone infused CardiaMend patch in the operating room and applied onto the epicardial surface biatrially

Primary outcome measure

  • Safety, defined as major adverse cardiac and cerebrovascular events (MACCE), up to subject discharge. [ Time Frame: From the day of the index procedure up to two months or date of hospital discharge, whichever is the sooner ]

Central Contacts and Locations

Central contacts

Jaimin Trivedi, MBBS FACC

502-588-7638jaimin.trivedi@louisville.edu

Chief Operating Officer, Helios Cardio Inc., PhD

339-707-7799pjackson@helioscardio.com

Locations

University of Louisville

Recruiting

Louisville, Kentucky, United States, 40202

Contacts

Jaimin Trivedi, MD FACC

708-606-3115jaimin.trivedi@louisville.edu

Terry Blanton, BSN RN

502-587-4381mary.blanton@louisville.edu

More Information

Sponsor

Helios Cardio Inc.

Last update posted

Dec 12, 2024

Last verified

Dec, 2024

Keywords

  • post Operative Atrial Fibrillation
  • Arrhythmias
  • Cardiac Heart Diseases
  • Cardiovascular Diseases
  • Atrial Fibrillation
  • Anti-Arrhythmia Agents

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Helios Cardio Inc. on 2024-12-12.